About Codexis, Inc.
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
2BBBullish & Bearish
Codexis, Inc. (CDXS) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 25 out of 100.
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
Codexis, Inc.’s current 2BB score is 25 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 7 | Very Low |
| Momentum | 46 | Stable |
| Financial strength | 15 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 49 | Moderate |
| CEO | John Nicols |
| Headquarters | Redwood City, California, United States |
| Founded | 2002 |
| Employees | 146 |
| 52-week range | $0.96 – $3.87 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -0.0969 | — | $18.57M |
| 2026-08-11 | -0.13 | -0.1408 | $14.92M | $14.64M |
| 2026-05-07 | -0.1 | -0.1394 | $15.25M | $14.82M |
| 2026-03-11 | 0.11 | -0.0428 | $38.91M | $36.55M |